The GLP-1 Pill Era Arrived. The Easy Trade Is Over.
The obesity drug went oral, the global patent wall started cracking, and the next-gen pipeline began sorting winners from pretenders. The demand was never the question — who manufactures cheapest and copies fastest is.
For three years, the GLP-1 trade had one shape: buy Novo Nordisk, buy Eli Lilly, and watch two companies print money from injectable obesity drugs the world couldn't manufacture fast enough. It was the cleanest macro story in healthcare — secular demand, pricing power, supply scarcity, and a total addressable market measured in hundreds of millions of patients.
That trade is now over. Not the demand — the demand is only accelerating. What's over is the simplicity. In the span of six months, three things happened at once that broke the old playbook: the obesity drug went oral, the global patent wall started to crack, and the next-generation pipeline began separating winners from pretenders. The money in obesity is still there. It's just not sitting where it was.
This is the part of the story that matters for capital, and it's the part most investors are still pricing as if it's 2024.
The pill era actually arrived
The single most important structural shift in this market is convenience, and 2026 is the year it landed.
On December 22, 2025, the FDA approved Novo Nordisk's 25mg oral Wegovy — the first oral GLP-1 cleared for chronic weight management — with a full U.S. launch in January 2026. In the OASIS 4 trial, the pill delivered roughly 16.6% mean weight loss among adherent patients. That's genuinely competitive with injections. The catch: oral semaglutide is a peptide, so it must be taken on an empty stomach, in the morning, 30 minutes before food or water. Real-world adherence to that regimen is the open question.
Then on April 1, 2026, Lilly got Foundayo (orforglipron) approved — and here's where the competitive map redraws. Orforglipron isn't a peptide. It's a small molecule. Patients can take it any time of day, with or without food. Its efficacy is lower — around 12% weight loss in ATTAIN-1 versus injectables and oral semaglutide — but the manufacturing and convenience implications are enormous, and we'll get to why that matters more than the efficacy gap.
Two pills, two completely different chemistries, two completely different cost structures. The market is treating this as "both companies have a pill now." That's the wrong frame.
The patent wall is cracking — but not where America is looking
The second shift is one almost nobody in the U.S. retail crowd is tracking, because it isn't happening in the U.S.
Novo's American semaglutide patent doesn't expire until 2032. But data exclusivity in a string of major markets falls away starting now: Canada's semaglutide exclusivity lapsed in January 2026, with China, Brazil, and India close behind. Generic and biosimilar makers — Dr. Reddy's, Sandoz, Apotex and others — have been staging semaglutide copies for exactly this window. Dr. Reddy's already has a semaglutide biosimilar in global registration for Canada, Brazil, and India.
This is a multi-billion-dollar volume story unfolding entirely outside the market most American investors watch. And it changes who captures the next hundred million patients.
The CagriSema stumble, the manufacturing bottleneck that quietly decides this whole war, the specific ex-U.S. names with the most to gain, and how to actually position around all of it — that's where this gets actionable.
This is where the analysis gets actionable. AlphaBriefing members get the full investment framework — scenarios, positioning, and the bottom line.
Subscribe to AlphaBriefing — Free, Member, and Paid tiers available.